Indegene Ltd

Indegene Ltd

Indegene Ltd announced its financial results for the quarter ended September 30, 2026, with revenue of ₹11,223M ($117.5M), up 39.5% YoY, and EBITDA of ₹1,873M at 16.7% margin, up 32.0% YoY.

Indegene Ltd

Indegene Ltd has announced the resignation of Ms. Srishti Ramesh Kaushik as Company Secretary, Compliance Officer, and Key Managerial Personnel, effective December 2, 2026. The Board has also approved unaudited financial results for the 2nd quarter and half year ended September 30, 2026, and other matters.

Indegene Ltd

Indegene Ltd has announced the allotment of shares under RSU Scheme 2020 and ESOP Scheme 2020, along with unaudited financial results for the 2nd quarter and half year ended September 30, 2026. The company has also noted the resignation of two directors and the re-constitution of the Nomination and Remuneration Committee and Investment Committee.

Indegene Ltd

Indegene Ltd has announced unaudited financial results for the 2nd quarter and half year ended September 30, 2026. The Board of Directors has approved the results along with a limited review report from the auditors. The company has also approved allotment under the RSU Scheme 2020 and ESOP Scheme 2020. Additionally, the Board has noted and accepted the resignation of two key personnel, Mr. Mark Francis Dzialga and Ms. Srishti Ramesh Kaushik, and reconstituted the Nomination and Remuneration Committee and Investment Committee.

Indegene Ltd

Indegene Ltd has announced the outcome of its Board Meeting held on October 29, 2026, where it approved unaudited standalone and consolidated financial results for the 2nd quarter and half year ended September 30, 2026, and also approved allotment under RSU Scheme 2020 and ESOP Scheme 2020. The Board also noted the resignation of two directors and reconstituted the Nomination and Remuneration Committee and Investment Committee.

Indegene Ltd

Indegene Ltd has incorporated a step-down wholly owned subsidiary, Indegene Portugal, Unipessoal LDA, in Portugal. The subsidiary is 100% owned by Indegene Ireland Limited, a wholly owned subsidiary of Indegene Ltd. The entity is yet to begin operations.

Indegene Ltd

Indegene Ltd has received Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for its AI-powered pharma commercialization services.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a non-executive, non-independent director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director. The details of the cessation are not provided.

Indegene Limited

Indegene Limited has informed BSE about the cessation of a Non-Executive Non-Independent Director.